Molecular basis for necitumumab inhibition of EGFR variants associated with acquired cetuximab resistance

Acquired resistance to cetuximab, an antibody that targets the epidermal growth factor receptor (EGFR), impacts clinical benefit in head and neck, and colorectal cancers (CRC). One of the mechanisms of resistance to cetuximab is the acquisition of mutations that map to the cetuximab epitope on EGFR...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cancer Ther
Autors principals: Bagchi, Atrish, Haidar, Jaafar N., Eastman, Scott W., Vieth, Michal, Topper, Michael, Iacolina, Michelle D., Walker, Jason M., Forest, Amelie, Shen, Yang, Novosiadly, Ruslan D., Ferguson, Kathryn M.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5925748/
https://ncbi.nlm.nih.gov/pubmed/29158469
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0575
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars